Ascelia Pharma AB (publ)

ACE.ST

Biotechnology · Healthcare

Exchange

Stockholm Stock Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

Ascelia Pharma is a Swedish clinical-stage biotechnology company focused on developing drugs for patients with serious diseases, particularly cancer. Its lead product is Orviglance (mangafodipir), a contrast agent designed to improve MRI scans in patients with liver problems who cannot safely use standard contrast agents. The company targets hospitals and radiologists as its end customers.

Ascelia Pharma makes no product revenue yet because its drugs are still in clinical development and have not received full regulatory approval for commercial sale. The company is based in Malmö, Sweden, and operates primarily in Europe, though it aims for broader international markets. With a deeply negative return on invested capital and zero gross margin, the business currently runs entirely on external funding, and its key risk is whether Orviglance can clear remaining regulatory hurdles and reach commercial launch — without that approval, the company faces ongoing cash burn and potential dilution for existing shareholders.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+43.5% YoY

YoY Growth Rate

Strong earnings growth

Insider Activity

12.0%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Runway

~6 months

kr 34M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Ascelia Pharma AB (publ) has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-85.8%

Weak — -85.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial